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Abstract: The description more than 30 years ago of the role of de novo purine synthesis in 
T and B lymphocytes clonal proliferation opened the possibility for selective immunosuppression 
by targeting speciﬁ  c enzymatic pathways. Mycophenolic acid (MPA) blocks the key enzyme 
inosine monophosphate dehydrogenase and the production of guanosine nucleotides required 
for DNA synthesis. Two MPA formulations are currently used in clinical transplantation as 
part of the maintenance immunosuppressive regimen. Mycophenolate mofetil (MMF) was the 
ﬁ  rst MPA agent to be approved for the prevention of acute rejection following renal transplan-
tation, in combination with cyclosporine and steroids. Enteric-coated mycophenolate sodium 
(EC-MPS) is an alternative MPA formulation available in clinical transplantation. In this review, 
we will discuss the clinical trials that have evaluated the efﬁ  cacy and safety of MPA in adult 
kidney transplantation for the prevention of acute rejection and their use in new combination 
regimens aiming at minimizing calcineurin inhibitor toxicity and chronic allograft nephropathy. 
We will also discuss MPA pharmacokinetics and the rationale for therapeutic drug monitoring 
in optimizing the balance between efﬁ  cacy and safety in individual patients.
Keywords: kidney transplantation, immunosuppression, mycophenolic acid, mycophenolate 
mofetil, enteric-coated mycophenolate sodium, acute rejection, chronic allograft nephropathy
Introduction
The outcome of solid organ transplantation during the past two decades has been 
tightly linked to the development of new immunosuppressive drug therapies.1–4 The 
advent of calcineurin inhibitors (CNI), cyclosporine (CsA) in the 1980s and tacro-
limus (TAC) in the 1990s, together with anti-T-cell induction therapies resulted in 
a spectacular improvement of one-year allograft survival when compared to the 
previous combination of azathioprine and corticosteroids.4–6 The primary focus of 
immunosuppressive protocols has always been the prevention of acute allograft rejec-
tion, a leading cause of graft loss during the ﬁ  rst year after transplantation and a risk 
factor for the development of chronic allograft dysfunction and poor long-term graft 
outcome. However, while the rates of acute rejection episodes and short-term patient 
and allograft survival have steadily improved under CNI-based immunosuppressive 
regimens, optimal long-term allograft survival remains a problem.6–8 Indeed, despite 
potent anti-rejection therapies, there is still an inexorable loss of transplanted organs 
due to chronic allograft dysfunction, also referred to as chronic allograft nephropathy 
(CAN) in kidney transplantation, a process involving immunological factors and non-
immunological drug-related toxicity.9,10 Besides increased cardiovascular risk factors 
such as hypertension, hyperlipidemia and diabetes leading to increased patient mor-
bidity and mortality, CNI have been associated with nephrotoxicity and vasculopathy, 
contributing to CAN. Thus, research efforts are now focused on ﬁ  nding efﬁ  cacious 
immunosuppressive drug regimens with less graft and patient toxicity.
In this paper, we review the efﬁ  cacy and safety of mycophenolic acid (MPA) formula-
tions in human adult kidney transplantation. Based on the results of three major clinical Therapeutics and Clinical Risk Management 2009:5 342
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trials, mycophenolate mofetil (MMF) was the ﬁ  rst MPA agent 
to be approved for the prevention of acute rejection following 
renal transplantation, in combination with CsA and steroids. 
The results of these initial trials including long-term follow-up 
data of the study population and subgroup analysis will be 
discussed, as triple therapy of CsA-MMF-prednisone has 
since become the standard maintenance immunosuppression 
in many renal transplantation centers. We will also review 
trials evaluating MMF in new combination regimens aiming at 
minimizing CNI toxicity and CAN, as well as the use of enteric-
coated mycophenolate sodium (EC-MPS), an alternative MPA 
formulation. Finally, because of the complex pharmacokinetics 
of MPA resulting in inter- and intra-patient variability in drug 
exposure, therapeutic drug monitoring (TDM) of MPA could 
provide further improvement in the clinical management of 
individual patients and optimal immunosuppression.
Cellular targets of MPA 
and pharmacology
T-cells play a central role in the immune response to an 
allograft and most current immunosuppressive drugs target 
T-cell activation and/or clonal expansion. Once T-cells have 
been speciﬁ  cally primed through their T-cell receptor (TCR) 
by alloantigens, the calcium-calcineurin pathway is activated, 
leading to the expression of survival and proinﬂ  ammatory 
cytokines and their receptors. The engagement of the IL-2 
receptor delivers growth and proliferation signals via the 
down-stream phophoinositide-3-kinase (PI3K) and the 
mammalian target-of-rapamycin (mTOR) pathways, initi-
ating the cell cycle. Whereas CNI (CsA and TAC) inhibit 
the calcium-calcineurin pathway and alloantigen-dependent 
T-cell activation, MPA inhibits T- and B-cell proliferation 
(Figure 1).
The role of de novo purine synthesis in lymphocyte clonal 
proliferation was ﬁ  rst highlighted by the characterization of 
patients with inherited immunodeﬁ  ciency syndromes and 
the identiﬁ  cation of key enzymatic pathways.11 MPA was 
originally obtained from a Penicillium fungus and shown 
to have anti-neoplastic, anti-viral, anti-fungal and immuno-
suppressive activities.12–14 MPA selectively and reversibly 
blocks an important step in the de novo synthesis of purine 
by inhibiting inosine monophosphate (IMP) dehydrogenase, 
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Figure 1 Potential targets for immunosuppressive drugs.   Three distinct signals are required for the activation and differentiation of alloreactive T-cells into proliferating effector 
T-cells. In addition to antigen recognition, full T-cell activation requires a costimulatory signal (signal 2) provided by the antigen-presenting cell (APC). The activation of signal 1 and 2 
initiates a cascade of downstream signaling pathways and the induction of transcription factors, leading to the expression of new surface molecules such as inducible costimulatory 
molecules and cytokine receptors. Interleukin-2 (IL-2) and other cytokines can then deliver growth and proliferation signals (signal 3) via the phophoinositide-3-kinase (PI3K) and 
the mammalian target-of-rapamycin (mTOR) pathways, initiating the cell cycle. Whereas calcineurin inhibitors (cyclosporine and tacrolimus) inhibit the calcium-calcineurin pathway 
and alloantigen-dependent T-cell activation, anti-proliferative agents (azathioprine, mycophenolic acid [MPA], mTOR-inhibitors) inhibit lymphocyte proliferation. MPA selectively 
blocks an important step in the de novo synthesis of purine by inhibiting inosine monophosphate dehydrogenase (IMPDH), an essential pathway for lymphocyte division.
Abbreviation: NFAT, nuclear factor of activated T cells.Therapeutics and Clinical Risk Management 2009:5 343
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an enzyme that allows the conversion of IMP to xanthosine 
monophosphate, the precursor of guanosine nucleotides 
required for DNA synthesis (Figure 1).15 MPA has no effect 
on the other route of purine nucleotide synthesis, the salvage 
pathway, where guanine obtained from the breakdown of 
nucleic acids is directly converted into guanosine monophos-
phate. Unlike neutrophils, lymphocytes depend primarily 
on the de novo purine synthesis pathway and may be more 
speciﬁ  cally targeted by MPA. In addition, different isoforms 
of IMP dehydrogenase exist, and MPA has a higher bind-
ing afﬁ  nity for the type II isoform, which is upregulated in 
stimulated lymphocytes. Thus, MPA preferentially inhibits 
the division of activated lymphocytes, and, on theoretical 
grounds, would result in a better targeted immunosuppression 
with fewer side-effects that the less selective anti-metabolite 
azathioprine (AZA).
In vitro and in vivo studies have shown that MPA inhibits 
the generation of cytotoxic T cells and prevents antibody 
production by B cells, but has no direct effect on the produc-
tion of cytokines.16 The synthesis of glycoproteins such as 
leukocyte surface adhesion molecules (selectins and integ-
rins) is dependant on guanosine nucleotides. MPA treatment 
may thus also interfere with the recruitment of lymphocytes 
to sites of inﬂ  ammation and their interaction with the endo-
thelium of a vascularized allograft.17
Mycophenolate mofetil (MMF, CellCept®)
MMF, formerly called RS-61443, is an ester prodrug of MPA 
with better bioavailability (94%). After oral administration 
and absorption, the ester is rapidly cleaved, releasing the 
active MPA component with a maximum plasma concentra-
tion at 2 hours. MPA then undergoes hepatic glucuroconju-
gation to form an inactive glucuronide metabolite (MPAG) 
which is eliminated in the urine (90%) or excreted into the 
bile. In the gut, bacterial enzymes can convert this metabolite 
back to MPA, which is reabsorbed into circulation (entero-
hepatic recirculation), leading to a secondary plasma peak 
of MPA 6 to 12 hours after oral administration.18 The mean 
elimination half-life of MPA is 8 to 16 hours.
Enteric-coated mycophenolate sodium 
(EC-MPS, Myfortic®)
Because the use of MMF has been associated with a high 
incidence of gastrointestinal (GI) adverse events, a new 
MPA formulation was developed. EC-MPS lacks the mofetil 
ester and releases MPA only when the alkaline environment 
of the small intestine is reached. Dissolution studies with 
EC-MPS have shown that MPA is maximally released at 
pH 6.0 to 6.8.19 Pharmacokinetic studies in renal transplant 
patients have demonstrated that EC-MPS 720 mg twice a day 
provides an MPA exposure bioequivalent to MMF 1 g twice 
a day and has a comparable safety proﬁ  le.19,20 A subsequent 
meta-analysis of pharmacokinetic data from three clinical 
trials (n = 82 patients) conﬁ  rmed the bioequivalence of 
EC-MPS and MMF for both MPA and metabolite exposure, 
and for maximum plasma MPA concentrations.21
Efﬁ  cacy of MMF in current 
immunosuppressive regimens 
after kidney transplantation
Current established immunosuppressive strategies in kidney 
transplantation often include an induction agent (monoclonal 
or polyclonal anti-T-cell antibodies) based on the immu-
nologic risk of the recipient, followed by a maintenance 
regimen combining a CNI and an anti-proliferative agent, 
with or without corticosteroids.2–4 As MMF was the ﬁ  rst 
MPA formulation approved in clinical kidney transplantation, 
more extensive clinical data are available with this drug in 
comparison to EC-MPS.
MMF therapy for the prevention of acute 
allograft rejection in cyclosporine-based 
regimens
The primary objective for the addition of MMF to mainte-
nance immunosuppression was to reduce the rate of acute 
rejection. Three large multicenter, prospective, randomized, 
double-blinded trials have evaluated MMF therapy for the 
prevention of acute allograft rejection in ﬁ  rst or second 
renal cadaveric transplantation: the European Mycophe-
nolate Mofetil Cooperative Study, US Renal Transplant 
Mycophenolate Mofetil Study Group, and the Tricontinental 
Mycophenolate Mofetil Renal Transplantation Study Group 
which was performed in Europe, Canada and Australia.22–24 
Overall, these trials included 55 transplantation centers and 
were the largest immunosuppressive prospective random-
ized drug trials ever performed in transplantation. In the US 
and Tricontinental trials, MMF (2 g/day and 3 g/day) was 
compared to AZA, with concomitant treatment of CsA and 
corticosteroids in all the groups. Anti-thymocyte globulin 
was given in the US trial, while patients received no induc-
tion therapy in the Tricontinental trial. In the European trial, 
MMF (2 g/day and 3 g/day) was compared to a placebo. In 
this trial, all the groups were also under CsA-prednisone 
maintenance therapy, but none received induction therapy. 
The primary end-point for all three trials was treatment Therapeutics and Clinical Risk Management 2009:5 344
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failure, deﬁ  ned as biopsy-proven acute rejection, graft loss, 
patient death or withdrawal from the study during the ﬁ  rst 
6 months after transplantation. All three trials also reported 
drug related side-effects.
One-year efﬁ  cacy data from these three trials were evalu-
ated in a pooled analysis.25 Altogether, 1493 patients had 
been randomized, with 505, 490 and 498 patients in MMF 
2 g/day, 3 g/day and AZA/placebo groups, respectively. 
The incidence of biopsy-proven acute rejection within the 
ﬁ  rst year was signiﬁ  cantly lower in transplant recipients 
treated with MMF (19.8% and 16.5% for MMF 2 g/day 
and 3 g/day, respectively) compared to patients receiving 
AZA or placebo (40.8%). In addition, the rejection episodes 
were less severe in the MMF groups as evaluated by Banff 
scores on biopsies (9.9%, 8.1% and 23.9% grade II or more 
severe histological scores in MMF 2 g/day, 3 g/day and 
AZA/placebo treatment groups, respectively) and the require-
ment for high-dose steroids and anti-lymphocyte antibodies. 
There was however no signiﬁ  cant difference in graft function 
(evaluated by mean serum creatinine), nor in graft and patient 
survival in the ﬁ  rst year, within the treatment groups. Of note, 
study withdrawal due to adverse events was more common 
in MMF groups (8.7%, 14.7% and 5.2% in MMF 2 g/day, 
3 g/day and AZA/placebo treatment groups, respectively). GI 
toxicity (mainly diarrhea, esophagitis and gastritis) was more 
frequent under MMF compared to AZA therapy, but in most 
cases improved following a decrease in MMF dose and it did 
not result in study discontinuation. Opportunistic infections 
occurred in all treatment groups but tissue-invasive CMV was 
more common in the MMF treatment groups. There was no 
report of hepatotoxicity; neutropenia and thrombocytopenia 
were infrequent, while anemia was similarly observed in 
MMF and AZA treatment groups.
Three-year follow-up data have been published for the 
Tricontinental and European trials.26,27 In the Tricontinental 
study, overall graft survival and function remained compa-
rable in all treatment groups. However, patients who had 
experienced biopsy-proven rejection within 6 months after 
transplantation were more likely (26.1% vs 5.7%) to lose their 
transplant at 3 years compared to patients free from early 
acute rejection, and, graft loss due to rejection was reduced 
in patients receiving MMF (5.8%, 3.0% and 9.9% in MMF 
2 g/day, 3 g/day and AZA treatment groups, respectively). 
This illustrated the potential negative impact of early acute 
rejection episodes on long-term graft outcome as previously 
reported.28 In the European study, treatment of recipients 
with MMF 2 g/day resulted in a signiﬁ  cant increase in graft 
survival at 3 years (84.8%, 81.2% in MMF 2 g/day and 
3 g/day, respectively) compared to placebo (78%). In both 
studies, no new signiﬁ  cant adverse event occurred during 
the second and third year following transplantation. These 
later follow-up AZA/placebo-controlled studies have thus 
established the safety and efﬁ  cacy of MMF treatment in 
renal transplantation.
Since the introduction of MMF, the original oil-based 
formulation of CsA has been largely replaced by the micro-
emulsion formula of cyclosporine in immunosuppressive 
regimens after renal transplantation. The efﬁ  cacy and toler-
ability of MMF in combination with CsA-microemulsion and 
prednisone was studied in ﬁ  rst-time recipients of cadaveric 
or living-donor renal transplants.29 Treatment failure and the 
cumulative rate of acute rejection were signiﬁ  cantly lower in 
the MMF treatment group compared with the AZA treatment 
group (p = 0.007 and p = 0.03, respectively). Death and 
safety proﬁ  les were similar in both treatment groups over 
the12-months study period, indicating that MMF can be 
combined with CsA-microemulsion and prednisone for main-
tenance immunosuppression after renal transplantation.
MMF as therapy in acute allograft 
rejection
Following on these initial data, randomized trials have 
established the potential of MMF in the treatment of acute 
rejection episodes as an alternative and as an adjuvant therapy 
to high-dose corticosteroids30–32 in renal transplant recipients 
treated primarily with CsA-prednisone maintenance 
immunosuppression. In combination with intravenous 
corticosteroids, MMF 3 g/day was significantly more 
effective than AZA and reduced the need for anti-lymphocyte 
antibodies (29.2% vs 51.9%). It was also shown that under 
MMF therapy, subsequent rejection episodes, graft loss or 
death were less likely compared to AZA (38.9% vs 65.7%) 
during the 3 years after transplantation. Renal function of 
the surviving grafts at 3 years was however similar in both 
treatment groups.32
Besides reducing the incidence of early acute rejection 
episodes, immunosuppressive protocols combining CsA and 
MMF have been shown to reduce late allograft rejection, thus 
improving long-term patient and graft survival. Data analysis 
of 47693 primary renal allograft recipients, reported to the 
United States Renal Data System (USRDS) between 1988 
and 1998, has shown that long-term continuous MMF therapy 
was associated with a 65% decreased risk of developing 
late acute rejection (beyond 1 year after transplantation) as 
compared to AZA (RR = 0.35, CI 0.27–0.45, p  0.001).33 
In this study population the rate of acute rejection episodes in Therapeutics and Clinical Risk Management 2009:5 345
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the AZA treatment group was 6.1% at 2 years and 9.3% at 
3 years, vs 0.9% and 1.1% at 2 and 3 years after transplanta-
tion in the MMF group, respectively.33
MMF therapy in combination 
with tacrolimus
The initial usage of MMF in renal transplantation was in 
combination with CsA and steroids. With the advent of 
new immunosuppressive drugs, subsequent prospective 
randomized trials have evaluated MMF in combination 
regimens with these agents. Several studies have demonstrated 
the pharmacologic synergism between MMF and tacrolimus 
(TAC).34 A few large multi-center randomized trials have 
evaluated the risk of acute rejection in adult cadaveric kid-
ney-transplant recipients under a combination therapy of 
TAC-MMF-steroids compared to TAC-steroids, TAC-AZA-
steroids or CsA-MMF-steroids.35–39 TAC-MMF-steroids 
therapy was superior to TAC-steroids in preventing acute 
rejection (27% vs 44%).35 In one study, TAC-AZA-
steroids and TAC-MMF 1 g/day-steroids resulted in similar 
efﬁ  ciency in preventing acute rejection (35,6% vs 34.9% 
acute rejection episodes), while TAC-MMF 2 g/day-steroids 
appeared to provide greater protection (8.9%) but without 
significant improvement in graft or patient survival at 
1 year. Furthermore, patients in the MMF 2 g/day treatment 
group had their total daily dosage often reduced due to GI 
or hematological side-effects, so that at 6 months the mean 
daily dose in this group was 1.5 g/day.36 In another trial with 
1-2- and 3-year follow-up, there was no signiﬁ  cant difference 
in the incidence of acute rejection, graft and patient survival 
between TAC-MMF-steroids, TAC-AZA-steroids and 
CsA-MMF-steroids treatment groups.37–39 Median serum 
creatinine levels were higher in the CsA treatment group 
compared to the TAC-based regimens. Of note, among 
the subset of patients with delayed graft function, there 
was a signiﬁ  cant improvement in graft survival under the 
TAC-MMF combination therapy (84%, 70% and 61% for 
TAC-MMF-steroids, TAC-AZA-steroids and CsA-MMF-
steroids, respectively). In summary, these studies have 
provided evidence that TAC-MMF-prednisone triple therapy 
was safe and equally effective than CsA-MMF-prednisone in 
preventing acute rejection in renal transplantation. Moreover 
the short-term results of the recent large prospective Efﬁ  cacy 
Limiting Toxicity Elimination (ELITE) – Symphony study 
in de novo renal transplantation, suggest that TAC-MMF-
prednisone maintenance immunosuppression may even be 
advantageous for graft function and survival, with lower 
acute rejection rates.40 In this study 1645 kidney-transplant 
recipients were randomized in 4 treatment groups: 
standard-dose CsA-MMF-prednisone (CsA target trough 
levels 130–300 ng/mL for 3 months, then 100–200 ng/mL), or 
daclizumab induction with MMF-prednisone in combination 
with low-dose CsA (target trough levels 50–100 ng/mL), 
low-dose TAC (target trough levels 3–7 ng/mL), low-dose 
sirolimus (SRL, target trough levels 4–8 ng/mL). At 12 months 
after transplantation, a lower rate of biopsy-proven acute 
rejection occurred in patients receiving low-dose TAC 
(12.3%, 25.8%, 24%, 37.2% for low-dose TAC, standard-
dose CsA, low-dose CsA, or low-dose SRL treatment groups, 
respectively) and renal function was better preserved than in 
the other three groups (mean calculated GFR 65.4 mL/min 
vs range 56.7–59.4 mL/min, p  0.001).
MMF in high-immunologic risk patients
The reported successes of CsA-MMF-prednisone maintenance 
immunosuppression in adult low-immunologic risk kidney-
transplant recipients has led to the evaluation of MMF 
safety and efﬁ  cacy in high risk recipients such as in pediatric 
transplantation41 as well as for adult African-Americans.42,43 In 
a post-hoc analysis of ethnic subgroups done in the US  study,24 
the rate of biopsy-proven acute rejection was higher in any 
of the treatment groups among African-American compared 
to Caucasian recipients. African-Americans had more severe 
rejection episodes and higher serum creatinine levels at 
6 months after transplantation, regardless of the treatment 
group, but data indicated that they had an additional beneﬁ  t 
from the 3 g vs 2 g/day MMF dose in association with CsA 
and steroids (47.5%, 31.8%, 12% incidence of acute rejection 
for AZA, MMF 2 g/day, MMF 3 g/day treatment groups, 
respectively).42
MMF in CNI-sparing immunosuppressive 
regimens
The addition of MMF to CNI-based maintenance 
immunosuppresssion has signiﬁ  cantly reduced the rates of 
acute rejection in the ﬁ  rst year after transplantation, however 
without a signiﬁ  cant impact in long-term (ie, 5 years) graft 
and patient outcome. CNI are a major cause of poor graft and 
patient survival more that 1 year after transplantation as they 
can contribute to CAN and are associated with increased car-
diovascular risk factors.7–10 Reducing CNI dosage or avoiding 
CNI could therefore be an approach to improve long-term 
outcome in renal transplantation.44 Thus, the introduction of 
potent anti-proliferative agents such as MMF in maintenance 
immunosuppressive regimens may allow CNI-minimization 
without increasing the immunological risk.Therapeutics and Clinical Risk Management 2009:5 346
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As CNI-MMF maintenance immunosuppression was 
shown to prevent long-term failure of kidney grafts, 
independent of its effect on early and late acute rejection 
episodes,33,45,46 randomized multi-center prospective studies 
have further investigated the impact of MMF-based regimens 
after CNI minimization or withdrawal. The aims were either 
to avoid chronic nephrotoxicity in patients with stable kidney 
function,47–53 or to improve/maintain kidney function in the 
presence of CAN (deﬁ  ned by declining renal function and/or 
characteristic histological changes on protocol biopsies).54–61
In the ﬁ  rst prospective clinical trials evaluating the safety 
of CsA-withdrawal strategies in renal transplantation, recipi-
ents with stable graft function on CsA-MMF-prednisone 
maintenance therapy over 1 year after transplantation were 
randomized to remain on CsA-MMF-prednisone standard 
therapy or MMF-prednisone treatment arm.47,48 Renal 
function as well as some cardiovascular risk factors such as 
serum cholesterol levels signiﬁ  cantly improved after CsA 
withdrawal. Acute rejection rates at 6 months (10.6% vs 
2.4%) and 5 years (16% vs 1%) were signiﬁ  cantly higher 
in the CsA-withdrawal group versus controls, without 
however an impact on patient and graft survival rates at 
5 years.48 To preserve renal function without increasing 
the risk of immunologic injury, CNI-reduction strategies 
(50% dose-reduction) have been successfully reported.49
Based on the encouraging results obtained with the switch 
(1 year after transplantation) to low-dose CNI maintenance 
immunosuppression in recipients with stable renal function, 
multi-center prospective randomized studies investigated the 
efﬁ  cacy and safety of de novo (ie, at the time of transplantation) 
low-dose CNI-MMF-prednisone and MMF-prednisone 
(CNI-avoidance) immunosuppressive regimens in renal trans-
plantation. To control the immunological risk in these settings, 
recipients either received induction therapies with anti-T-cells 
antibodies40,50,51 and/or an additional anti-proliferative agent 
such as an mTOR-inhibitor.52,62–65 In the CAESAR study, 
CsA-minimization under the cover of basiliximab did not 
result in signiﬁ  cant improvement of renal function and the 
incidence of biopsy-proven acute rejection was signiﬁ  cantly 
higher in the CsA-withdrawal group (38%) as compared to the 
low-dose CsA (25.4%) or standard dose CsA (27.5%) groups 
(p  0.05).50 Interestingly, in comparison, the basiliximab 
induction followed by low-dose TAC-MMF-prednisone 
immunosuppressive regimen used in the ELITE–Symphony 
study resulted in improved 1-year graft function with lower 
acute rejection rates.40
Following extensive preclinical studies, a recent 
multi-center randomized phase II kidney transplantation 
clinical trial has investigated the efﬁ  cacy and safety of 
belatacept, a molecule that blocks T-cell activation and is 
not known to be nephrotoxic, as an alternative to CNI in 
maintenance immunosuppression.53 One-year results showed 
similar acute rejection rates in both arms (19% vs 18% in 
belatacept-MMF-prednisone and CsA-MMF-prednisone 
groups, respectively), while in the belatacept treatment 
group renal function was signiﬁ  cantly improved with a lower 
prevalence of CAN on protocol biopsies.
CNI dose-reduction was also attempted under the cover of 
MMF-prednisone in recipients with declining renal function 
and CAN conﬁ  rmed on biopsies.54–61 In general, in these trans-
plant recipients, serum creatinine levels stabilized or decreased 
after CNI-minimization and the switch from AZA-prednisone 
to MMF-prednisone maintenance immunosuppression, 
without an increase in the incidence of acute rejection. Thus, 
these observational and randomized clinical trials suggest that 
it could be a safe and effective therapeutic option in selected 
renal transplant recipients with worsening renal function. 
Furthermore, the reduction or complete withdrawal of CNI 
could also improve metabolic parameters and blood pressure 
control and decrease patient’s cardiovascular morbidity.61
Safety and efﬁ  cacy of EC-MPS 
versus MMF
Side-effects associated with MMF
The majority of data concerning the safety and tolerability of 
MMF in transplant recipients were obtained from the three 
earliest prospective randomized double-blinded clinical tri-
als in renal transplantation, evaluating MMF at 2 g/day and 
3 g/day.22–24 Long-term trials of patients with psoriasis treated 
with MMF are also available.66 Overall, MMF was well 
tolerated with most of the symptoms being dose-dependant 
as the reported side-effects generally resolved with the 
reduction of the dose. In these studies, GI toxicity (mainly 
diarrhea, nausea, esophagitis and gastritis) and tissue-
invasive CMV were more common with MMF therapy, 
while myelosuppression (mainly leucopenia and anemia, 
only rarely neutropenia) and other opportunistic infections 
also occurred in AZA treatment groups. GI side-effects can 
occur in up to 45% of patients treated with MMF and are in 
part due to systemic MPA exposure and its antiproliferative 
effect on enterocytes.22–24,67 Dose reductions or temporarily 
discontinuation of MMF may be sufﬁ  cient to relieve the 
symptoms but can result in sub-therapeutic levels.
EC-MPS is an alternative formulation of MPA, designed 
to reduce GI toxicity. In a few multi-center prospective 
open-label studies, MMF-treated kidney-transplant patients Therapeutics and Clinical Risk Management 2009:5 347
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experiencing GI complaints were successfully converted 
to equimolar doses of EC-MPS.68,69 These studies have 
shown that following the switch to EC-MPS, GI-related 
symptoms and health-related quality of life, as assessed 
by self-administered patient questionnaires, improved 
signiﬁ  cantly68 and this was a sustained effect over time after 
conversion to EC-MPS.69
Bioequivalence, safety and tolerability 
of EC-MPS in renal transplantation
Randomized clinical trials in renal transplantation have 
evaluated MPA drug exposure and the bioequivalence of 
EC-MPS compared to MMF, as well as the therapeutic efﬁ  -
cacy and safety of EC-MPS in renal transplantation, either 
de novo after transplantation as part of CNI-based mainte-
nance immunosuppression or after a switch from MMF.70–72 
The ERL B301 Study group, an international, randomized, 
double-blind trial, has assessed the therapeutic equivalence 
of EC-MPS (720 mg bid) and MMF (1000 mg bid), with 
concomitant CsA microemulsion and corticosteroids, in 423 
de novo kidney-transplant patients.70,71 At 12 months, the 
incidence of biopsy proven acute rejection, graft loss or death 
was 26.3% and 28.1% (biopsy proven acute rejection alone 
22.5% and 24.3%) for EC-MPS and MMF, respectively. The 
safety proﬁ  le and interestingly the incidence of GI adverse 
events were similar for both groups.70 In the extension study, 
after 1 year of treatment the patients ﬁ  rst randomized in the 
MMF group were converted to EC-MPS, and both groups 
were followed for 2 more years.71 The overall incidence of 
adverse events, acute rejection and graft loss during the exten-
sion phase was comparable to that seen in the core study, 
and in the MMF arm of other similar controlled randomized 
studies. This study established the long-term efﬁ  cacy and 
tolerability of EC-MPS in association with CsA and steroids, 
as well as the safety of converting renal transplant patients 
from MMF to EC-MPS.
The myfortic Prospective Multicentre Study (myPROMS) 
was an international, prospective, open-label, clinical trial 
designed to assess the efﬁ  cacy and safety of EC-MPS in 
combination with CsA microemulsion in a large population 
of kidney-transplant recipients.73–75 The study had a pre-
deﬁ  ned core protocol with 14 sub-studies addressing different 
aspects related to EC-MPS treatment. All participants were 
treated with EC-MPS and CsA microemulsion (C2 level 
monitoring), with or without corticosteroids, and induc-
tion therapy was given as per center practice. The primary 
efﬁ  cacy evaluation was the rate of treatment failure, deﬁ  ned 
as biopsy-proven acute rejection, graft loss or death of the 
recipient during the ﬁ  rst 6 and 12 months after transplanta-
tion. Safety and tolerability analyses were also performed for 
all patients, including reported adverse-events, hematology 
and chemistry proﬁ  les, infections and malignancies. Data 
were pooled from multiple centers for planned analysis of 
sub-protocols.
In a 6-month sub-study (Asia, Europe, and Latin 
America), the efﬁ  cacy and safety of converting stable renal 
transplant recipients (n = 564) from MMF to a bioequivalent 
dose of EC-MPS were evaluated.73 Patients who were at least 
at 3 months post transplantation (ie, maintenance patients) 
and had a stable graft function under CsA-MMF with or 
without corticosteroids therapy were eligible to enter the 
subprotocol. After switch from MMF to EC-MPS, renal 
function remained stable throughout the trial (baseline 
calculated creatinine clearance 65.3 ± 20.4 mL/min 
and 66.9 ± 21.4 mL/min at month 6) and the rate of treat-
ment failure was low (1.9% of which 1.7% biopsy-proven 
acute rejection within 6 months of converting to study 
medication, no episodes of graft loss). EC-MPS was well 
tolerated with only mild to moderate severity adverse-events 
(6.5% hematological, 23.5% GI), leading to dose reductions 
(6.3%) or drug interruption (3.4%). The results of this large 
multi-center study provided further proof of the safety 
and maintained efﬁ  cacy of EC-MPS compared to MMF 
in maintenance immunosuppression for renal transplant 
recipients.
Another pooled analysis of three myPROMS sub-studies 
(US01, DE01, FR01 substudies performed in USA, Germany 
and France, respectively) evaluated the efﬁ  cacy and toler-
ability of EC-MPS de novo in renal transplantation. All 
patients received steroids and basiliximab induction and 
were randomized in standard or low-dose CsA, and early 
(day 0) or delayed (day 6 after transplantation) CsA intro-
duction treatment groups.74 There was 25.9% treatment 
failure reported at 12 months after transplantation (22.1% 
biopsy-proven acute rejection, 3.1% graft loss) and renal 
function was stable (median calculated creatinine clearance 
62.9 mL/min). There was no signiﬁ  cant difference between 
CsA treatment groups at month 6 and 12 in terms of biopsy-
proven acute rejection, graft and patient survival and graft 
function. High EC-MPS dosing was sustained throughout the 
study period (90% recommended dose) and dose modiﬁ  ca-
tions due to EC-MPS-related adverse-events or infections 
were infrequent. Similarly, we have analysed a sub-group 
of 140 de novo kidney-transplant recipients from 11 centers 
in Europe, treated with EC-MPS and CsA microemulsion 
with or without steroids.75 The incidence of treatment failure, Therapeutics and Clinical Risk Management 2009:5 348
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biopsy-proven acute rejection and graft loss was comparable 
at 6 and 12 months (18.6% vs 22.1%, 15.7% vs 19.3%, 
and 1.4% vs 2.1%, at 6 and 12 months, respectively) with 
preserved renal function (calculated creatinine clearance 
63.2 ± 27.1 mL/min at 12 months). In summary, these pooled 
analysis have shown that EC-MPS given in combination with 
CsA microemulsion, steroids and IL-2-receptor antagonist 
induction offers effective and well-tolerated immunosup-
pression in de novo renal transplantation.
MPA exposure and therapeutic drug monitoring
Based on the results of pivotal large prospective randomized 
trials, MMF was approved for the prevention of acute 
rejection in renal transplantation in combination with 
CsA and steroids.22–24 But unlike other maintenance 
immunosuppressive drugs such as CNI or mTOR inhibitors, 
MMF was introduced into routine clinical practice on a 
ﬁ  xed-dose recommendation (2 or 3 g/day). As discussed, 
these standard-dose regimens have overall proven to be 
efﬁ  cient in preventing early acute rejection as well as late 
rejection and graft failure. However, it has been shown that 
for an identical oral dose of MMF, there is an intra- and 
inter-patient variability of the pharmacokinetics of MPA. 
Indeed, factors such as renal function, serum albumin 
and bilirubine, concurrent medication (in particular CsA), 
altered GI absorption, and host genetics may inﬂ  uence MPA 
exposure.76,77 Thus, ﬁ  xed-dose MMF therapy may lead to 
under- or over-immunosuppression leading to increased 
risk of acute rejection or drug toxicity, respectively. Clini-
cal studies have reported a signiﬁ  cant correlation between 
incidence of acute rejection and MPA plasma concen-
trations.78–80 Therapeutic drug monitoring of the active 
metabolite MPA pharmacokinetic parameters would allow 
optimizing the efﬁ  cacy and safety of immunosuppression 
and a more individualized-based treatment.81
The most reliable measure of MPA exposure is 
the 12-hour area under the plasma concentration-time 
curve (AUC0–12). The measurement however implies blood 
samples drawn over a 12-hour time interval and is not 
feasible in routine clinical practice. Predose measurement 
(trough levels) of MPA is an alternative to AUC, but is less 
accurate due to greater within-patient variability. Simpliﬁ  ed 
limited sampling AUC strategies have been proposed and 
evaluated in renal transplant patients at various time-points 
after transplantation.80,82–84 These strategies have been shown 
to accurately estimate individual MPA AUC using a limited 
number of blood samples and are now being used for MPA 
dose-adaptation in concentration-controlled studies in clinical 
practice. Moreover, as the biological activity of MPA may 
be more relevant than its pharmacokinetic parameters in 
correlating with clinical outcome, an assay based on the 
measurement of IMP deshydrogenase activity in peripheral 
blood mononuclear cells has been reported.85 The beneﬁ  t of 
TDM in renal transplantation outcome was evaluated in a 
12-month prospective French trial (APOMYGRE), with 137 
transplant recipients randomized to receive either concentra-
tion-controlled or ﬁ  xed-dose MMF, together with basiliximab 
induction, CSA and steroids.80 The incidence of treatment 
failure (a composite of death, graft loss, acute biopsy-proven 
rejection, MMF discontinuation) was signiﬁ  cantly lower 
in the concentration-controlled group (29.2% vs 47.7%), 
which interestingly received a higher MMF dose in the ﬁ  rst 3 
months after transplantation. Compared to MMF, equimolar 
doses of EC-MPS result in similar MPA exposure, but there 
are less data available on TDM for EC-MPS and the correla-
tion with clinical outcome.86
Because of technical difﬁ  culties, costs and concerns about 
the optimal methodology to use, controversies exist whether 
TDM of the active metabolite MPA should be applied to 
all renal transplant recipients.87,88 Based on the association 
between clinical events and MPA exposure and the known 
pharmacokinetic variability, TDM has been recommended in 
deﬁ  ned clinical settings to establish adequate individualized 
MPA levels.89 In the ﬁ  rst weeks after transplantation, patients 
with concurrent CsA administration were found to have 
MPA AUC below target levels with MMF 2 g/day. CSA, as 
opposed to TAC, inhibits the enterohepatic recirculation of 
MPA, resulting in lower MPA concentrations and potential 
under-exposure. Thus, TDM would be useful in the immedi-
ate post transplantation period, in high immunological risk 
patients, when reducing or withdrawing CSA or switching 
from/to another immunosuppressant such as TAC or mTOR 
inhibitors. It would also allow to monitor the overall degree of 
immunosuppression during a clinical event such as rejection 
or the occurrence of severe side-effects.
Conclusion and perspectives
In order to improve allograft and patient survival, the main 
objective of current immunosuppressive regimens is to 
prevent acute rejection episodes which may negatively 
impact on short and long-term outcomes, while limiting 
drug-related toxicity including CAN. Because of the good 
safety proﬁ  le and great efﬁ  cacy of MMF demonstrated 
in large randomized pivotal trials, most transplantation 
programs now routinely use MPA formulations rather than 
AZA in their immunosuppressive maintenance regimens. Therapeutics and Clinical Risk Management 2009:5 349
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The use of MPA formulations, both MMF and EC-MPS, 
can however be limited by their side-effects (mainly GI and 
hematological) especially in advanced renal failure, as well 
as higher costs compared to AZA. In this regard, it is worth 
noting that the early prospective randomized trials that have 
lead to “standard” CsA-MMF-prednisone triple therapy 
had used an old formulation of CsA. A recent multi-center 
prospective randomized cadaveric renal transplantation study 
(Mycophenolate Steroids Sparing, MYSS trial), comparing 
the efﬁ  cacy of MMF (2 g/day) to AZA (75–100 mg/day) 
in combination with the CsA-microemulsion formulation 
(Neoral) and steroids showed no clear advantage of MMF 
over AZA in preventing early (6 months after transplan-
tation) as well as late (6 months after transplantation) 
occurring acute rejection.90 In the extension of MYSS, the 
follow-up study, graft function, incidence of late rejections 
and adverse events, graft and patient survival were compa-
rable among both treatment groups at 5-years follow-up. The 
authors concluded that in kidney transplantation, short as well 
as long-term efﬁ  cacy proﬁ  les of MMF and AZA therapy in 
combination with CsA-microemulsion were similar.91 They 
also pointed out that MMF treatment was about 15 times 
more expensive.
Overall, the addition and type of induction therapy, the 
type and dosage of CNI versus other anti-proliferative agents 
such as mTOR-inhibitors in maintenance immunosuppressive 
regimens together with MMF may impact differently on 
the rate of acute allograft rejection and graft survival. 
Further large prospective long-term studies are needed 
to better determine the combination therapy that would 
provide optimal graft and patient outcome. In addition, 
treatment based on TDM would provide individualized 
immunosuppression and may help optimize the efﬁ  cacy-
toxicity proﬁ  le of immunosuppressive drugs and further 
improve clinical outcome. Cost-effectiveness should also 
be an issue in the choice of medication as well as the type 
of monitoring of standard immunosuppressive regimens for 
renal transplant recipients.
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